News

The diagnosis of mast cell activation syndrome can be complicated by overlap with SM, dysautonomia and hereditary alpha tryptasemia.

Unlike in patients from Western countries, anaphylaxis was rarely a sign of SM in Southeast Asian patients.

Experts called for treatment goals beyond symptom control when defining clinical remission in SM and other allergic diseases.

New real-world data reports on the efficacy of pegylated interferon-α for treating systemic mastocytosis and other hematologic neoplasms.

Mast cell counts and the tryptase depletion index showed substantial overlap across groups and did not reliably distinguish MCAS from SM or other conditions.

Treatment with 25 mg of avapritinib led to meaningful and lasting symptom improvements during a three-year follow up.

A real-world study found that indolent SM is linked to a high symptom burden and increased rates of bone disease compared with matched controls.

A recent study evaluates the link between medication allergies and systemic mastocytosis, focusing on high-risk drugs like NSAIDs.

Most children with mastocytosis limited to the skin improve or fully resolve, often within a few years, rather than progress to SM.

Needle-free epinephrine to treat anaphylaxis could reduce hesitation, improve portability and increase access to this life-saving drug.